Soraia Attie Calil Jorge

Dr. Soraia Attie Calil Jorge


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 July 2021 in Molecular Biotechnology
Verified
Journal Article
Closed access
PDF file
TBThaissa Consoni Bernardino
Thaissa Consoni Bernardino
RARenato Mancini Astray
Renato Mancini Astray
CPCarlos Augusto Pereira
Carlos Augusto Pereira
VBVera Lucia Boldorini
Vera Lucia Boldorini
MAMarta Maria Antoniazzi
Marta Maria Antoniazzi
Soraia Attie Calil JorgeSoraia Attie Calil Jorge
Soraia Attie Calil Jorge

29 December 2022 in Journal of Biotechnology
Verified
Journal Article
Closed access
LGLuis Giovani Oliveira Guardalini
Luis Giovani Oliveira Guardalini
PCPaulo Eduardo da Silva Cavalcante
Paulo Eduardo da Silva Cavalcante
JLJaci Leme
Jaci Leme
RMRenata Gois de Mello
Renata Gois de Mello
TBThaissa Consoni Bernardino
Thaissa Consoni Bernardino
ENEutimio Gustavo Fernandez Nunez
Eutimio Gustavo Fernandez Nunez

12 June 2023 in Frontiers in Pharmacology
Verified
Journal Article
Open access
RMRenata Gois de Mello
Renata Gois de Mello
TBThaissa Consoni Bernardino
Thaissa Consoni Bernardino
LGLuis Giovani Oliveira Guardalini
Luis Giovani Oliveira Guardalini
RARenato Mancini Astray
Renato Mancini Astray
MAMarta Maria Antoniazzi
Marta Maria Antoniazzi
Soraia Attie Calil JorgeSoraia Attie Calil Jorge
Soraia Attie Calil Jorge
Introdutcion: The Zika virus (ZIKV) infections are a healthcare concern mostly in the Americas, Africa, and Asia but have increased its endemicity area beyond these geographical regions. Due to the advances in infections by Zika virus, it is imperative to develop diagnostic and preventive tools against this viral agent. Virus-like particles (VLPs) appear as a suitable approach for use as antiviral vaccines.Methods: In this work, a methodology was established to produce virus-like particles containing the structural proteins, C, prM, and E of Zika virus produced in insect cells using the gene expression system derived from baculovirus. The vector pFast- CprME -ZIKV was constructed containing the gene sequences of Zika virus structural proteins and it was used to generate the recombinant bacmids (Bac- CprME -ZIKV) through transformation into DH10BacTM cells. The Bac- CprME -ZIKV was transfected in Spodoptera frugiperda (Sf9) insect cells and batches of BV- CprME -ZIKV were obtained by infection assays using a multiplicity of infection of 2. The Sf9 cells were infected, and the supernatant was collected 96 h post-infection. The expression of the CprME -ZIKV protein on the cell surface could be observed by immunochemical assays. To concentrate and purify virus-like particles, the sucrose and iodixanol gradients were evaluated, and the correct CprME -ZIKV proteins’ conformation was evaluated by the Western blot assay. The virus-like particles were also analyzed and characterized by transmission electron microscopy.Results and discussion: Spherical structures like the native Zika virus from 50 to 65 nm containing the CprME -ZIKV proteins on their surface were observed in micrographs. The results obtained can be useful in the development path for a vaccine candidate against Zika virus.

10 May 2023 in Molecular Biotechnology
Verified
Journal Article
Closed access
PDF file
LGLuis Giovani Oliveira Guardalini
Luis Giovani Oliveira Guardalini
JLJaci Leme
Jaci Leme
PCPaulo Eduardo da Silva Cavalcante
Paulo Eduardo da Silva Cavalcante
RMRenata Gois de Mello
Renata Gois de Mello
TBThaissa Consoni Bernardino
Thaissa Consoni Bernardino
Soraia Attie Calil JorgeSoraia Attie Calil Jorge
Soraia Attie Calil Jorge

24 December 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
LGLuis Giovani Oliveira Guardalini
Luis Giovani Oliveira Guardalini
PCPaulo Eduardo da Silva Cavalcante
Paulo Eduardo da Silva Cavalcante
JLJaci Leme
Jaci Leme
RMRenata Gois de Mello
Renata Gois de Mello
TBThaissa Consoni Bernardino
Thaissa Consoni Bernardino
Soraia Attie Calil JorgeSoraia Attie Calil Jorge
Soraia Attie Calil Jorge
This work aimed to assess, following upstream optimization in Schott flasks, the scalability from this culture platform to a stirred-tank bioreactor in order to yield rabies-recombinant baculovirus, bearing genes of G (BVG) and M (BVM) proteins, and to obtain rabies virus-like particles (VLP) from them, using Sf9 insect cells as a host. Equivalent assays in Schott flasks and a bioreactor were performed to compare both systems and a multivariate statistical approach was also carried out to maximize VLP production as a function of BVG and BVM’s multiplicity of infection (MOI) and harvest time (HT). Viable cell density, cell viability, virus titer, BVG and BVM quantification by dot-blot, and BVG quantification by Enzyme-Linked Immunosorbent Assay (ELISA) were monitored throughout the assays. Furthermore, transmission electron microscopy was used to characterize rabies VLP. The optimal combination for maximum VLP expression was BVG and BVM MOI of 2.3 pfu/cell and 5.1 pfu/cell, respectively, and 108 h of harvest time. The current study confirmed that the utilization of Schott flasks and a benchtop bioreactor under the conditions applied herein are equivalent regarding the cell death kinetics corresponding to the recombinant baculovirus infection process in Sf9 cells. According to the results, the hydrodynamic and chemical differences in both systems seem to greatly affect the virus and VLP integrity after release.

1 December 2014 in Journal of Biotechnology
Verified
Journal Article
Closed access
SSSandra Fernanda Suárez-Patiño
Sandra Fernanda Suárez-Patiño
RARenato Astray
Renato Astray
CPCarlos Augusto Pereira
Carlos Augusto Pereira
CSClaudio Alberto Torres Suazo
Claudio Alberto Torres Suazo
RMRonaldo Zucatelli Mendonça
Ronaldo Zucatelli Mendonça
Soraia Attie Calil JorgeSoraia Attie Calil Jorge
Soraia Attie Calil Jorge